BNTC 8-K: SEC filing

Benitec Biopharma

Filed with the SEC on · accession 0001193125-26-459339

BNTC filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Benitec Biopharma announced its financial results for the fiscal quarter ended September 30, 2026, and its Board of Directors approved a change in the company's fiscal year-end from June 30 to December 31, effective November 12, 2026.

Key details

RegistrantBenitec Biopharma Inc.
Chief executive officerDr. Jerel A. Banks

✦ Ask GOAX AI about this filing — what it means for BNTC, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BNTC?

Click here

Frequently asked questions

What did BNTC file with the SEC on Nov 13, 2026?

BNTC filed a 8-K (SEC filing). Benitec Biopharma announced its financial results for the fiscal quarter ended September 30, 2026, and its Board of Directors approved a change in the company's fiscal year-end from June 30 to December 31, effective November 12, 2026.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other BNTC SEC filings

Get alerts when BNTC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days